- In April 2023, Illumina Inc., a global leader in DNA sequencing and array-based technologies, partnered with Janssen Biotech Inc. to expand the application of whole-genome sequencing (WGS) for identifying rare and undiagnosed genetic diseases. This strategic collaboration aims to accelerate research and improve early diagnosis capabilities, reinforcing Illumina’s commitment to advancing genomic medicine and expanding the reach of genetic testing in complex disease areas
- In March 2023, 23andMe Holding Co., a prominent player in the direct-to-consumer genetic testing segment, launched a new pharmacogenetics report as part of its health service offerings. This report helps consumers understand how their genetic profile may affect their response to certain medications. The move highlights the growing demand for personalized health insights and reflects 23andMe’s ongoing efforts to integrate clinically relevant testing into consumer-accessible platforms
- In February 2023, Myriad Genetics Inc. announced the release of its updated MyRisk Hereditary Cancer Test, featuring a new panel with expanded gene coverage and enhanced predictive accuracy. This development aims to provide broader insights for individuals at risk of hereditary cancers such as breast, ovarian, and colorectal cancers. Myriad’s innovation emphasizes the role of genetic testing in early cancer detection and risk assessment, supporting personalized preventive strategies
- In February 2023, Thermo Fisher Scientific Inc. launched its Ion Torrent Genexus Dx Integrated Sequencer, a fully automated next-generation sequencing (NGS) platform designed for clinical diagnostics. This system allows for same-day results with minimal hands-on time, marking a significant advancement in workflow efficiency and clinical decision-making. The launch reinforces Thermo Fisher’s focus on enabling precision medicine through accessible, high-throughput genetic testing solutions
- In January 2023, Invitae Corporation entered into a strategic partnership with NTT DATA to expand access to its genetic testing platform in emerging markets. This collaboration aims to enhance global reach and reduce barriers to genetic diagnostics by leveraging digital health infrastructure. The partnership reflects Invitae’s mission to make comprehensive genetic information accessible and actionable for all patients, particularly in underrepresented regions
